$CELG News Celgene stock price target cut to $
Post# of 102254
Posted On: 01/29/2016 12:14:49 PM
$CELG News
Celgene stock price target cut to $120 from $130 at Barclays 8:23 a.m. Today - Tomi Kilgore
Why this big baby of a market won’t calm down anytime soon 9:23 a.m. Jan. 28, 2016 - Victor Reklaitis
Celgene earnings miss as costs offset price hike 8:42 a.m. Jan. 28, 2016 - MarketWatch.com
Apple, Amazon headline crucial week for Wall Street quarterly results 6:21 a.m. Jan. 25, 2016 - Wallace Witkowski
Celgene started at outperform with $149 stock price target at Credit Suisse 8:16 a.m. Jan. 20, 2016 - Tomi Kilgore
10 biotech stocks to buy at ‘silly’ cheap prices 10:15 a.m. Jan. 18, 2016 - Michael Brush
As biotech stocks knife under their ‘Hillary’ low, analysts still say buy ’em 7:27 a.m. Jan. 12, 2016 - Victor Reklaitis
Celgene names new CEO, cuts 2015 outlook 1:45 p.m. Jan. 11, 2016 - MarketWatch.com
Shire agrees to buy Baxalta for $32 billion 8:49 a.m. Jan. 11, 2016 - MarketWatch.com
Shire agrees to buy Baxalta for $32 billion 8:16 a.m. Jan. 11, 2016 - MarketWatch.com
Celgene’s stock rockets as analysts cheer patent settlement 4:40 p.m. Dec. 23, 2015 - Tomi Kilgore
Dow posts triple-digit gain for third session in a row 4:27 p.m. Dec. 23, 2015 - Sara Sjolin
10 stocks that led the S&P 500 higher Wednesday 4:26 p.m. Dec. 23, 2015 - Philip van Doorn
Celgene shares jumps 8.4% in early trade as company settles patent suit 9:34 a.m. Dec. 23, 2015 - Mark DeCambre
Celgene shares lead S&P 500 gainers 9:34 a.m. Dec. 23, 2015 - Mark DeCambre
Celgene's stock surges 8.7% premarket after settlement of Revlimid patent litigation late Tuesday 8:59 a.m. Dec. 23, 2015 - Tomi Kilgore
Bulls ready to break out of the holiday quiet 8:45 a.m. Dec. 23, 2015 - Victor Reklaitis
Celgene shares rally on settlement of patent suit 5:00 p.m. Dec. 22, 2015 - Wallace Witkowski
Celgene shares rally 10% after patent litigation settled 4:45 p.m. Dec. 22, 2015 - Wallace Witkowski
AstraZeneca to buy 55% stake in Acerta Pharma 3:15 a.m. Dec. 17, 2015 - MarketWatch.com
SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates 34 min ago - Zacks.com
Stock Market News for January 29, 2016 10:10 a.m. Today - Zacks.com
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook 9:05 a.m. Today - Zacks.com
Biotech ETF (IBB) Hits New 52-Week Low 8:59 a.m. Today - Zacks.com
European Ad Comm backs Bristol-Myers and AbbVie's elotuzumab for multiple myeloma 8:44 a.m. Today - Seeking Alpha
Cramer Likes T-Mobile - Cramer's Lightning Round (1/28/16) 7:16 a.m. Today - Seeking Alpha
Wall Street Breakfast: BOJ Goes Sub-Zero In The Heart Of Winter 6:57 a.m. Today - Seeking Alpha
What To Buy In This Biotech Sell-Off 6:46 a.m. Today - Seeking Alpha
'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Market 'Trash' Will Make You Money 8:10 p.m. Jan. 28, 2016 - TheStreet.com
Celgene (CELG) Stock Plunged on Earnings Miss 4:52 p.m. Jan. 28, 2016 - TheStreet.com
'The Market Doesn't Know Where It's Headed' 4:02 p.m. Jan. 28, 2016 - TheStreet.com
Celgene Corporation's (CELG) CEO Robert J. Hugin on Q4 2015 Results - Earnings Call Transcript 3:31 p.m. Jan. 28, 2016 - Seeking Alpha
Stocks Back Near Highs in Unsettled Session 2:23 p.m. Jan. 28, 2016 - TheStreet.com
Incyte Halts Phase II Jakafi-Stivarga Combination Study 1:50 p.m. Jan. 28, 2016 - Zacks.com
Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues 11:43 a.m. Jan. 28, 2016 - Zacks.com
Celgene Earnings, Guidance Fail to Live Up to Investor Expectations 11:19 a.m. Jan. 28, 2016 - 247WallSt.com
Celgene Misses on Q4 Earnings, Reiterates 2016 Guidance 10:22 a.m. Jan. 28, 2016 - Zacks.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance 10:12 a.m. Jan. 28, 2016 - Zacks.com
Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now 9:39 a.m. Jan. 28, 2016 - 247WallSt.com
OncBioMune Patents a New Promising Approach to Chemotherapy 8:00 a.m. Jan. 28, 2016 - ACCESSWIRE
Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health 8:01 a.m. Jan. 25, 2016 - ACCESSWIRE
Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine 3:31 p.m. Jan. 22, 2016 - BusinessWire - BZX
Be Counted! Campaign Brings Together the Psoriatic Arthritis Community to Increase Understanding of This Chronic, Autoimmune Disease 8:00 a.m. Jan. 22, 2016 - BusinessWire - BZX
Investigational Combinations Using an ABRAXANE and Gemcitabine Foundation Lead ASCO GI Pancreatic Cancer Research 7:30 a.m. Jan. 22, 2016 - BusinessWire - BZX
Covered Call Alerts For Chesapeake Energy, BlackBerry, Nike, AbbVie and Celgene Released By InvestorsObserver 9:31 a.m. Jan. 19, 2016 - PR Newswire - PRF
Organizational Changes Strengthen Leadership Teamand Position Celgene for Long-Term Growth 11:06 a.m. Jan. 11, 2016 - BusinessWire - BZX
Covered Call Alerts For Disney, Celldex Therapeutics, Shake Shack, Dow Chemical and Celgene Released By InvestorsObserver 9:31 a.m. Jan. 6, 2016 - PR Newswire - PRF
Celgene Corporation to Announce Fourth Quarter and Full-Year 2015 Results on January 28, 2016 7:30 a.m. Jan. 5, 2016 - BusinessWire - BZX
Celgene Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference 7:30 a.m. Jan. 4, 2016 - BusinessWire - BZX
Covered Call Alerts For Kinder Morgan, Rite Aid, Celgene, ConocoPhillips and Amazon.com Released By InvestorsObserver 9:31 a.m. Dec. 24, 2015 - PR Newswire - PRF
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan 1:00 a.m. Dec. 21, 2015 - BusinessWire - BZX
Covered Call Alerts For Fitbit, Corning Inc., Celgene, CSX and Adobe Systems Released By InvestorsObserver 9:31 a.m. Dec. 14, 2015 - PR Newswire - PRF
BioSig Technologies, Inc. Issues Special Letter to Shareholders 8:01 a.m. Dec. 9, 2015 - Marketwired
Abstracts at San Antonio Breast Cancer Symposium Highlight ABRAXANE® as a Potential Backbone Therapy in Neoadjuvant and Triple-Negative-Breast Cancer 7:30 a.m. Dec. 9, 2015 - BusinessWire - BZX
Story Behind the Charts - Research on Celgene, United Continental Holdings, Yahoo! and Twitter 8:30 a.m. Dec. 8, 2015 - ACCESSWIRE
FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes 7:00 a.m. Dec. 7, 2015 - BusinessWire - BZX
IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research at ASH 7:00 a.m. Dec. 6, 2015 - BusinessWire - BZX
Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 12:30 p.m. Dec. 5, 2015 - BusinessWire - BZX
Study of Bortezomib Added to Revlimid® and Dexamethasone Backbone Therapy Presented at ASH 10:53 a.m. Dec. 5, 2015 - BusinessWire - BZX
Celgene stock price target cut to $120 from $130 at Barclays 8:23 a.m. Today - Tomi Kilgore
Why this big baby of a market won’t calm down anytime soon 9:23 a.m. Jan. 28, 2016 - Victor Reklaitis
Celgene earnings miss as costs offset price hike 8:42 a.m. Jan. 28, 2016 - MarketWatch.com
Apple, Amazon headline crucial week for Wall Street quarterly results 6:21 a.m. Jan. 25, 2016 - Wallace Witkowski
Celgene started at outperform with $149 stock price target at Credit Suisse 8:16 a.m. Jan. 20, 2016 - Tomi Kilgore
10 biotech stocks to buy at ‘silly’ cheap prices 10:15 a.m. Jan. 18, 2016 - Michael Brush
As biotech stocks knife under their ‘Hillary’ low, analysts still say buy ’em 7:27 a.m. Jan. 12, 2016 - Victor Reklaitis
Celgene names new CEO, cuts 2015 outlook 1:45 p.m. Jan. 11, 2016 - MarketWatch.com
Shire agrees to buy Baxalta for $32 billion 8:49 a.m. Jan. 11, 2016 - MarketWatch.com
Shire agrees to buy Baxalta for $32 billion 8:16 a.m. Jan. 11, 2016 - MarketWatch.com
Celgene’s stock rockets as analysts cheer patent settlement 4:40 p.m. Dec. 23, 2015 - Tomi Kilgore
Dow posts triple-digit gain for third session in a row 4:27 p.m. Dec. 23, 2015 - Sara Sjolin
10 stocks that led the S&P 500 higher Wednesday 4:26 p.m. Dec. 23, 2015 - Philip van Doorn
Celgene shares jumps 8.4% in early trade as company settles patent suit 9:34 a.m. Dec. 23, 2015 - Mark DeCambre
Celgene shares lead S&P 500 gainers 9:34 a.m. Dec. 23, 2015 - Mark DeCambre
Celgene's stock surges 8.7% premarket after settlement of Revlimid patent litigation late Tuesday 8:59 a.m. Dec. 23, 2015 - Tomi Kilgore
Bulls ready to break out of the holiday quiet 8:45 a.m. Dec. 23, 2015 - Victor Reklaitis
Celgene shares rally on settlement of patent suit 5:00 p.m. Dec. 22, 2015 - Wallace Witkowski
Celgene shares rally 10% after patent litigation settled 4:45 p.m. Dec. 22, 2015 - Wallace Witkowski
AstraZeneca to buy 55% stake in Acerta Pharma 3:15 a.m. Dec. 17, 2015 - MarketWatch.com
SurModics' (SRDX) Q1 Earnings & Revenues Beat Estimates 34 min ago - Zacks.com
Stock Market News for January 29, 2016 10:10 a.m. Today - Zacks.com
Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook 9:05 a.m. Today - Zacks.com
Biotech ETF (IBB) Hits New 52-Week Low 8:59 a.m. Today - Zacks.com
European Ad Comm backs Bristol-Myers and AbbVie's elotuzumab for multiple myeloma 8:44 a.m. Today - Seeking Alpha
Cramer Likes T-Mobile - Cramer's Lightning Round (1/28/16) 7:16 a.m. Today - Seeking Alpha
Wall Street Breakfast: BOJ Goes Sub-Zero In The Heart Of Winter 6:57 a.m. Today - Seeking Alpha
What To Buy In This Biotech Sell-Off 6:46 a.m. Today - Seeking Alpha
'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Market 'Trash' Will Make You Money 8:10 p.m. Jan. 28, 2016 - TheStreet.com
Celgene (CELG) Stock Plunged on Earnings Miss 4:52 p.m. Jan. 28, 2016 - TheStreet.com
'The Market Doesn't Know Where It's Headed' 4:02 p.m. Jan. 28, 2016 - TheStreet.com
Celgene Corporation's (CELG) CEO Robert J. Hugin on Q4 2015 Results - Earnings Call Transcript 3:31 p.m. Jan. 28, 2016 - Seeking Alpha
Stocks Back Near Highs in Unsettled Session 2:23 p.m. Jan. 28, 2016 - TheStreet.com
Incyte Halts Phase II Jakafi-Stivarga Combination Study 1:50 p.m. Jan. 28, 2016 - Zacks.com
Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues 11:43 a.m. Jan. 28, 2016 - Zacks.com
Celgene Earnings, Guidance Fail to Live Up to Investor Expectations 11:19 a.m. Jan. 28, 2016 - 247WallSt.com
Celgene Misses on Q4 Earnings, Reiterates 2016 Guidance 10:22 a.m. Jan. 28, 2016 - Zacks.com
Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance 10:12 a.m. Jan. 28, 2016 - Zacks.com
Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now 9:39 a.m. Jan. 28, 2016 - 247WallSt.com
OncBioMune Patents a New Promising Approach to Chemotherapy 8:00 a.m. Jan. 28, 2016 - ACCESSWIRE
Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health 8:01 a.m. Jan. 25, 2016 - ACCESSWIRE
Data Presented at ASCO GI Highlight the Feasibility of Second-Line Treatment in Patients with Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine 3:31 p.m. Jan. 22, 2016 - BusinessWire - BZX
Be Counted! Campaign Brings Together the Psoriatic Arthritis Community to Increase Understanding of This Chronic, Autoimmune Disease 8:00 a.m. Jan. 22, 2016 - BusinessWire - BZX
Investigational Combinations Using an ABRAXANE and Gemcitabine Foundation Lead ASCO GI Pancreatic Cancer Research 7:30 a.m. Jan. 22, 2016 - BusinessWire - BZX
Covered Call Alerts For Chesapeake Energy, BlackBerry, Nike, AbbVie and Celgene Released By InvestorsObserver 9:31 a.m. Jan. 19, 2016 - PR Newswire - PRF
Organizational Changes Strengthen Leadership Teamand Position Celgene for Long-Term Growth 11:06 a.m. Jan. 11, 2016 - BusinessWire - BZX
Covered Call Alerts For Disney, Celldex Therapeutics, Shake Shack, Dow Chemical and Celgene Released By InvestorsObserver 9:31 a.m. Jan. 6, 2016 - PR Newswire - PRF
Celgene Corporation to Announce Fourth Quarter and Full-Year 2015 Results on January 28, 2016 7:30 a.m. Jan. 5, 2016 - BusinessWire - BZX
Celgene Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference 7:30 a.m. Jan. 4, 2016 - BusinessWire - BZX
Covered Call Alerts For Kinder Morgan, Rite Aid, Celgene, ConocoPhillips and Amazon.com Released By InvestorsObserver 9:31 a.m. Dec. 24, 2015 - PR Newswire - PRF
Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan 1:00 a.m. Dec. 21, 2015 - BusinessWire - BZX
Covered Call Alerts For Fitbit, Corning Inc., Celgene, CSX and Adobe Systems Released By InvestorsObserver 9:31 a.m. Dec. 14, 2015 - PR Newswire - PRF
BioSig Technologies, Inc. Issues Special Letter to Shareholders 8:01 a.m. Dec. 9, 2015 - Marketwired
Abstracts at San Antonio Breast Cancer Symposium Highlight ABRAXANE® as a Potential Backbone Therapy in Neoadjuvant and Triple-Negative-Breast Cancer 7:30 a.m. Dec. 9, 2015 - BusinessWire - BZX
Story Behind the Charts - Research on Celgene, United Continental Holdings, Yahoo! and Twitter 8:30 a.m. Dec. 8, 2015 - ACCESSWIRE
FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes 7:00 a.m. Dec. 7, 2015 - BusinessWire - BZX
IMiD® Combination Therapies Form Backbone of Multiple Myeloma Research at ASH 7:00 a.m. Dec. 6, 2015 - BusinessWire - BZX
Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 12:30 p.m. Dec. 5, 2015 - BusinessWire - BZX
Study of Bortezomib Added to Revlimid® and Dexamethasone Backbone Therapy Presented at ASH 10:53 a.m. Dec. 5, 2015 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼